Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onabotulinum toxin A - AbbVie

Drug Profile

Onabotulinum toxin A - AbbVie

Alternative Names: BoNTA; Botox; Botulinum toxin A injectable-AbbVie; GSK 1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; Vistabex

Latest Information Update: 31 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie; Allergan; GlaxoSmithKline; GSK; Johns Hopkins University; Queens University; Temple University; University of Illinois at Chicago; Wake Forest University School of Medicine
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Strabismus; Muscle spasticity; Blepharospasm; Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dysphonia; Facial wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Preregistration Hypertrophy
  • Phase III Muscle pain; Raynaud's disease
  • Phase II Carpal tunnel syndrome; Essential tremor; Gastrointestinal disorders; Herpes labialis; Interstitial cystitis; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Pain; Premature ejaculation
  • Phase I/II Pruritus
  • No development reported Benign prostatic hyperplasia; Constipation; Prostatitis
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 16 May 2024 AbbVie withdraws a phase II trial in Hernia in USA (IM, Injection) due to strategic considerations (NCT05606757)
  • 30 Apr 2024 Phase-III clinical trials in Hypertrophy in USA (IM) (NCT06399718)
  • 16 Feb 2024 Preregistration for Hypertrophy in China (IM), before February 2024 (AbbVie pipeline, February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top